Levi Garraway (Genentech)
The FDA adds a failed Alzheimer's drug to the 'breakthrough' club now looking for a near-term OK
Almost 10 years to the day since Roche first whipped up enthusiasm for gantenerumab as a potential blockbuster therapy for Alzheimer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
